Duke Hematologic Malignancies & Cellular Therapy

Division within @dukemedicine and multidisciplinary program within @DukeCancer focused in blood cancer, stem cell transplantation, and cell & gene therapy.

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

Congratulations to Dr. @LouisDiehl2, an incredible clinician and medical educator who is retiring after a storied career at @WRNMMC_DHA and @DukeCancer. Thank you for your service!

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

Finishing strong with Monday presentations by our @DukeCancer faculty at #ASH25! Featuring @AndreaSitlinger @ChenyuLinMD @tomleblancMD

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

Come interact with our faculty and trainees on the Sunday evening poster session #ASH25!

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

Come check out our @DukeCancer faculty presentations at #ASH25 on Saturday, December 6th!

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

A strong start to #ASH25 with @LindsayReinMD and #HarryErba kicking off the Friday Satellite Symposia!

[Duke Cancer @DukeCancer]

DCI is participating in a national clinical trial that could reshape the future of CAR T-cell therapy for patients with aggressive lymphoma.

https://t.co/GG6q0Jmx92

@DukeMedSchool | @DukeHealth | @DukeHMCT

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

A warm welcome to our newest faculty member, Dr. Alexander Dew! Dr. Dew joins @DukeCancer from Walter Reed, where he had served as director of autologous stem cell transplantation. He sees patients with plasma cell disorders, including #myeloma.

https://t.co/NbPXMkCx5C

[Chenyu Lin, MD @ChenyuLinMD]

CAR #HEMATOTOX is associated with brexu-cel response, survival, and neutrophil recovery in #ALLsm. Great collaboration with @MSKCancerCenter Yannis Valtis & Jae Park, and #ROCCA consortium @StanfordCancer @LoriMuffly @UChicagoLeuk @RoloffGreg. @DukeCancer

https://t.co/SW3mEvE5AM

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

Take a look at this @FrontiersIn mini-review of reduced & weekly dosing of selinexor in #myeloma, with senior author @Cristin53875581

https://t.co/AbEUi4MDlU

[AML Hub @AML_Hub]

📝 Updated data from the KOMET-007 trial, presented by Harry Erba at #EHA2025, show that ziftomenib with intensive induction therapy was well tolerated in patients with newly diagnosed NPM1m or KMT2Ar AML.

More news: https://t.co/UucMeHvxP4

#AMLsm #leusm #MedNews #MedEd

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

Congratulations to @DukeCancer faculty Dr. Yubin Kang for his new @CancerResearch CLIP award studying how targeting SK2 can enhance CAR T cell therapy efficacy in multiple myeloma #mmsm

https://t.co/eOFcea9ahg

[Targeted Oncology @TargetedOnc]

Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and response to treatment based on mutational analyses. #MDS | @tomleblancMD @DukeCancer

https://t.co/OHQYNeDOFx

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

Take a look at this review of advancements in countermeasures against #radiation injuries from the Centers for Medical Countermeasures against Radiation Consortium (CMCRC), with former @DukeHMCT division chief #NelsonChao as senior author.

https://t.co/JKtG83Gd6A

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

This @CIBMTR retrospective study showed that solid organ transplant outcomes following stem cell transplantation varied depending on the organ transplanted. Liver transplants had worse outcomes compared to kidney transplants. Featuring @horwi001 as a co-author.

https://t.co/boYBsyB97w

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

The BELLINI trial showed that Vd-ven had worse overall survival than Vd-placebo in patients with relapsed multiple #myeloma, indicating that #venetoclax should be avoided in the general R/R myeloma population. Featuring @Cristin53875581 as an author.

https://t.co/B0zvHomTOs

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

Congratulations to our faculty @tomleblancMD for this important work!

[Ryan Nipp, MD, MPH, MBA, FASCO @RyanNipp]

Multisite Randomized Trial of Inpatient #Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation.

https://t.co/D8VIk3jg65

@ASCO @JCO_ASCO @JCOOP_ASCO
#PallOnc #PalliativeCare #SuppOnc
@Areejmd @tomleblancMD @MGHCancerCenter

[Targeted Oncology @TargetedOnc]

Explore the complexities of chronic #GVHD symptoms, assessment, and innovative treatment strategies, including ruxolitinib and emerging therapies in this article from Targeted Oncology: https://t.co/ll0OeU2nP7 | @DukeHMCT @dukemedicine @DukeHealth

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

Preclinical and early phase clinical data suggests a role for dual #FLT3 and MDM2 inhibition using #quizartinib and #milademetan in FLT3-ITD mutated #AML, featuring faculty #HarryErba as a co-author. @CCR_AACR #leusm

https://t.co/IdPtV13cvC

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

This cross-sectional study in @JCOOP_ASCO showed that cancer survivors were more likely to get alcohol screening, with similar rates of alcohol intervention when needed, highlighting opportunities for improvement. Featuring Vice-Chief @AndreaSitlinger.

https://t.co/pUMXgj67fG

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

A multicenter study from the U.S. #MultipleMyeloma Immunotherapy Consortium demonstrated the safety and efficacy of #teclistamab in real-world patients, featuring @DukeU @ChenyuLinMD and #DanielSchrum @BloodCancerJnl #MMsm

https://t.co/hJANd60Edi